grant
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Organization MAYO CLINIC ROCHESTERLocation ROCHESTER, UNITED STATESPosted 1 Apr 2026Deadline 31 Mar 2031
NIHUS FederalResearch GrantFY2026Active Follow-upAddressAdolescent and Young AdultAfrican AmericanAfro AmericanAfroamericanAgeAreaBiologicalCancer ControlCancer Control ScienceCancer SurvivorCancersCareer Development AwardsCareer Development Awards and ProgramsCareer Development Programs K-SeriesCause of DeathClinicalClinical TrialsCohort StudiesCollaborationsDataData SourcesDevelopmentDiagnosisDisease-Free SurvivalEarly treatmentEligibilityEligibility DeterminationEnrollmentEpidemiologyEthnic OriginEthnicityEventEvent-Free SurvivalFDA Drug ApprovalFood and Drug Administration Drug ApprovalFoundationsFunding MechanismsGeneral PopulationGeneral Prognostic FactorGeneral PublicGeneralized GrowthGerminoblastic SarcomaGerminoblastomaGoalsGrantGrowthGuidelinesHealthHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHispanicHomeIncidenceIndividualIndustryInferiorInterventionK-AwardsK-Series Research Career ProgramsKnowledgeLaboratoriesLife ExpectancyLong-Term SurvivorsLymphomaMaintenanceMalignant Hematologic NeoplasmMalignant LymphomaMalignant NeoplasmsMalignant TumorMeasuresModelingMolecular EpidemiologyNHL patientsNational Clinical Trials NetworkNational Institutes of HealthNeighborhoodsNon-Hodgkin's LymphomaNonhodgkins LymphomaOutcomeParticipantPathologyPatient CarePatient Care DeliveryPatient Care ManagementPatient Outcomes AssessmentsPatient Reported MeasuresPatient Reported OutcomesPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPerformancePersonal SatisfactionPersonsPhysiologic pulsePopulationPrognosisPrognostic FactorPrognostic/Survival FactorProspective cohortProtocol ScreeningProviderPublic HealthPublicationsPulseQOLQuality of Life AssessmentQuality of lifeRaceRacesRegistriesRelapseReportingResearchResearch Career ProgramResearch ResourcesResourcesReticulolymphosarcomaRiskRisk AssessmentRisk FactorsRuralSEER ProgramSEER-Surveillance, Epidemiology, and End ResultsScientific PublicationSecond CancerSecond Primary CancersSecondary MalignancySecondary Malignant NeoplasmSubgroupSurveillance, Epidemiology and End ResultsSurveillance, Epidemiology, and End Results ProgramSurvey InstrumentSurveysSurvival RateSurvivorsSystemTimeTissue GrowthTreatment FailureUnited States National Institutes of HealthValidationactive followupagesbiobankbiologicbiorepositorycancer diagnosiscancer locationcancer sitecare for patientscare of patientscaring for patientsclinical riskclinical validationco-morbidco-morbiditycohortcohort research studycohort surveycomorbiditycomputer based predictiondata sharingdesigndesigningdevelopmentalearly experienceearly therapyenrollepidemiologicepidemiologicalfollow upfollow-upfollowed upfollowupfrailtyhomesimprovedimproved outcomeindexinglife-style factorlifestyle factorsmalignancymethods to study multiple-level influencesmulti-level analysismulti-level modelmultilevel analysismultilevel modelmultilevel modelingnational surveillanceneoplasm/cancernew approachesnew markernext generationnon-Hodgkin's lymphoma patientsnon-Hodgkins diseasenonHodgkin's lymphoma patientsnovelnovel approachesnovel biomarkernovel markernovel strategiesnovel strategyontogenypatient oriented outcomespatient populationpatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypespredictive biological markerpredictive biomarkerspredictive markerpredictive modelingpredictive molecular biomarkerpsychosocialracialracial backgroundracial originrecruitrisk prediction algorithmrisk prediction modelruralitysecondary cancersexsocialsocial health determinantsstandard of caresurvivorshiptherapy failuretreatment and outcometreatment strategytrendunderstudied cancervalidationswell-beingwellbeing
Description preview
In 2025, an estimated 80,350 people in the US will be diagnosed with non-Hodgkin lymphoma (NHL), and
19,390 will die from this cancer. NHL survival rates began improving in the 1990s with the advent of improved
treatment strategies, leading to the current 5-year survival rate of 74%. These trends led to a growth in the
number of NHL survivors,…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click